Skip to main content
User picture
Phone: +420585632048
Groups: DOCTORAL STUDENT, IMTM, LEM, STAFF

Doctoral training

Development and validation of luminescent HTS tool for discovery and optimization of novel combination of CFTR correctors and modifiers

Cystic fibrosis (CF) disease results from mutations in the CFTR gene that encodes for an epithelial membrane protein acting as a chloride ion channel and water transport regulator. The mutations affecting CFTR protein expression result in difficulties in processing, folding, function and/or trafficking to the membrane depending on the type of mutations. Future discoveries of CFTR modulators and correctors rely on screening many chemical libraries. To develop such a screening tool suitable for high-throughput screening (HTS), a cellular model based on the combination of CRISPR/Cas9 technology and HiBiT tag will be prepared.

Specialization: Pediatrics
Status: Ongoing from 2017.

About me

I am a researcher at the Faculty of Medicine and Dentistry, Palacky University Olomouc, and a Ph.D. candidate in the field of molecular biology and experimental medicine. My interests revolve around the strategic research and development of novel high-throughput screening tools. My research focuses on developing new HTS methods for drug discovery to treat various chronic diseases.

Journals

CENTORAME, A., D. DUMUT, M. YOUSSEF, M. ONDRA, I. KIANICKA, J. SHAH, R. PAUN, T. OŽDIAN, J. HANRAHAN, E. GUSEV, B. PETROF, M. HAJDÚCH, R. PISLARIU, J. DE SANCTIS, D. RADZIOCH
Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Frontiers inPharmacology. 2022, 13, 876842, ISSN: 1664-3224,  PDF.